1. Pink Sheet
  2. >>Geography
  3. >>Europe

European Countries Focus Horizon Scanning On Alzheimer’s Disease

BeNeLuxA Pre-Empts Access Challenges For Alzheimer's Disease

 
• By Francesca Bruce

Working out what’s on the horizon in terms of potential new treatments for Alzheimer’s disease should help countries prepare for the challenges that will be involved when it comes to determining patient access.

Ocean
Horizon scanning can help countries facilitate access to Alzheimer's disease treatments • Source: Alamy

A horizon scanning report on new developments in Alzheimer’s disease from the BeNeLuxA cross-country initiative aimed at improving access to innovative medicines has flagged up challenges that health care systems will face when the time comes to make the treatments available. Industry agrees the time is now to confront these issues, which include differences in data requirements between regulators and health technology assessment (HTA) bodies and high prices.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.